Weight Loss-GLP-1 – Prepared Physician
US$ 20.53
glp-1 receptor agonists side effects The cardiovascular of beyond obesity and type 2 diabetes: An anti-atherosclerotic action Frontiers | Exploring the multifaceted
Description
1 control group) resulting in an OR of 1.54 [CI 0.406.02]
A percentage of people will not be able to tolerate the new pharmacotherapies or achieve the individualised goals and others may not have long-term access to these treatments
Cited 2/3/16 Hansotia T, Drucker DJ (2005): Therapeutic Potential of the DPP-4 Inhibitors
The most commonly reported concerns include inadequate protein intake, lean mass loss, vitamin D deficiency, thiamine and other B-vitamin issues, iron depletion, anemia, and low calcium, magnesium, and potassium intake
